Archived Content

The content on this page is provided for reference purposes only. This content has not been altered or updated since it was archived.

Vaccines, Blood & Biologics

July 19, 2010 Approval Letter - Fluarix

Our STN: BL 125127/319

GlaxoSmithKline Biologicals
Attention: Judith Magner, MS
2301 Renaissance Boulevard, Building 510
P.O. Box 61540
King of Prussia, PA  19406-2772

Dear Ms. Magner:

This is a clarification to your approval letter of October 19, 2009, regarding the pediatric study fulfillment requirements.

Under the Pediatric Research Equity Act  (PREA) (21 U.S.C. 355c), all applications for new active ingredients, new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication in the pediatric age group unless this requirement is waived, deferred, or inapplicable.

We note that you have fulfilled the pediatric study requirement for all relevant pediatric age groups for this application.

We are waiving the pediatric study requirement for ages birth to < 6 months of age because necessary studies in this age group are impossible or highly impracticable and there is evidence strongly suggesting that Fluarix® would be ineffective in this pediatric group.

We will include information contained in the above-referenced supplement in your biologics license application file.

Sincerely yours,


Wellington Sun, M.D.
Division of Vaccines and
Related Products Applications
Office of Vaccines
Research and Review
Center for Biologics
Evaluation and Research
Attachment: Approved Final Draft Labeling

Resources for You

Page Last Updated: 08/17/2010
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English